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ABSTRACT 
Exposure to repetitive mild traumatic brain injury (mTBI) in athletes is recognized as a risk factor 
for chronic traumatic encephalopathy (CTE), marked by the deposition of hyperphosphorylated 
tau aggregates in neurons and astrocytes in a patchy distribution at the depths of cortical sulci.  
We have developed a new mTBI paradigm to explore chronic effects of repetitive concussive-
type injury over several months in a hTau mouse model with human tau genetic background. 
Mice were exposed totwo injuries weekly, over a period of 3 or 4 months and compared to non-
injured, sham animals. Behavioral, in vivo measures and a detailed neuropathological assessment 
were conducted 6months post-first injury. Our data confirm impairment in cerebral blood flow 
and white matter damage. This was accompanied by a two-fold increase in total tau levels and 
mild increases in tau oligomers/conformers and pTau (Thr231) species in the grey matter. There 
was no evidence of neurofibrillary/astroglial tangles, neuropil threads, or perivascular foci of tau 
immunoreactivity. Neurobehavioral deficits were observed in mTBI animals (i.e. disinhibition 
and impaired cognitive performance). These data support the relevance of this new mTBI injury 
model for studying consequences of chronic repetitive mTBI in humans, and role of tau in TBI.    
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INTRODUCTION 
Exposure to traumatic brain injury (TBI) is recognized as a risk factor for later development of 
chronic neurodegenerative disorders, in particular chronic traumatic encephalopathy (CTE) (1-
13).First described in boxers (14), CTE is now increasingly recognized in autopsy series of non-
boxer athletes from a wide range of sports, including American football (11,13,15-16), ice hockey 
(13), soccer (13,17) and rugby (18).  Though the neuropathology of CTE is complex and multi-
faceted (9), common to the cases described thus far are abnormal deposits of 
hyperphosphorylated tau in perivascular neurons and glia and in a patchy distribution towards the 
depths of cortical sulci (13; NINDS workshop- CTE consensus report). Furthermore, blows to the 
head during a single boxing bout are associated with increased total tau in the spinal fluid (19,20) 
and athletes (ice hockey) and military personnel exposed to a history of TBI demonstrate an 
increase in total tau and tau-C cleaved fragments in the plasma (21-23).  
 
The precise incidence and prevalence of CTE, including the threshold of susceptibility to CTE 
following exposure to TBI, is unknown. Typically, reports of CTE have come from individuals 
exposed to repetitive mTBI through contact related sports injuries, though the pathology has also 
been reported in individuals exposed to single moderate or severe TBI (9,24). Though data on 
longitudinal follow up is lacking, in the cases reported thus far the mean duration of exposure to 
mTBI in an athlete’s career ranged between 5 and 24 years (11,25). In addition, a majority of 
these athletes were exposed to mTBI from their high school years to their late twenties, and some 
during their mid to late thirties (13,25), with the suggestion that extent of pathology at autopsy 
correlates not only with age at death and number of years after retirement, but also with length of 
exposure to injury(13,26). 
 
At present there are no published epidemiological, longitudinal, cross-sectional, or prospective 
studies involving CTE. Thus far, all published autopsy cases have been retrospective studies 
typically involving small sample sizesand subject to selection bias and incomplete pre-mortem 
data. Together, these limitations make it difficult to derive a comprehensive understanding of the 
neuropathological sequelae of exposure to TBI. Further, many current pre-clinical models fail to 
recapitulate the clinical and neuropathological consequences of mTBI, the cumulative exposures 
typical of human sports-associated injuries or the pathologies of CTE. Therefore, there is a 
critical need to develop an animal model that is relevant to lifetime exposure, sports-associated, 
repetitive mTBI in humans.  
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To date, different animal models have been developed to explore the effects of repetitive TBI (26-
39), most of these experimental models utilize a closed skull mTBI paradigm involving a 
pneumatic or electromagnetic impactor or weight drop model. However, though these models 
have described consistent pathologies, such as white matter degradation and gliosis, findings in 
relation to tau pathologies have been less consistent, with some reporting increases in multiple 
pathogenic tau species following injury (27,28,32,34,36,39), while others do not (29-31,33,38). 
Moreover, in most of those studies that report evidence of tau dependent TBI pathology, the 
authors only examined acute time points after-injury, with only one study showing evidence of 
persistent tau pathology at chronic timepoints six months after injury (36). Our previous mTBI 
model in “aged” hTau mice that express the six isoforms of human tau on a null murine 
background demonstrated augmentation of tau pathology 3weeks after injury, however, this 
persistent tau pathology was not observed in younger hTau or wild-type mice exposed to mTBI 
following examinations up to 12 months post-injury (29,33,39, Mouzon et al., 2016 pers 
comm).It appears therefore that persistent tau pathology is lacking in most TBI models. 
Additionally, in all the models to date that have depicted increases in intra-axonal or intrasomal 
phosphorylated-tau (p-tau), other components of CTE-like pathology were absent, such as 
neurofibrillary or astroglial tangles, neuropil threads and perivascular p-tau; these difficulties, and 
relatively few successes, in recapitulating tau-associated pathologies after TBI perhaps reflecting 
failure to adequately model the required variables in human injury exposure, such as chronicity of 
impacts, age at exposure or duration of exposure to injuries(40). 
 
In this study we set out to develop a new paradigm for our previously established, successful 
mouse model of mTBI (29,33,35,39), in order to focus primarily on two main aspects: (i) the 
chronic pathological consequences following cumulative exposure to repeated mTBI over a 
prolonged exposure period, and (ii) the influence of a human tau genetic background on “tau 
pathology” following this exposure protocol in mTBI. With regard to the latter, we used the hTau 
mouse model (41) in which we previously demonstrated TBI-dependent tau pathology in ‘aged’ 
animals exposed to mTBI (39). In addition to examining protein biochemistry profiles in our 
model, we also present supplementary data characterizing brain lipid and peripheral inflammatory 
profiles and neurobehavioral measures.  
In this first report, we confirm a two-fold increase in total tau levels and mild increases in tau 
oligomers/conformers and pTau (Thr231) species in the grey matter up to three months after 
cessation of injury, which may be on a continuum of progressive and persistent TBI dependent 
tau pathology. 
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METHODS  
Animals 
Transgenic mice expressing Human Tau on a C57BL/6 and null murine tau background 
(generated as previously described - 41) were purchased from Jackson Laboratories, Bar Harbor, 
ME. All mice were12 weeks old at the start of this study (average weight, 18 g). Animals were 
housed in standard cages under a 12-hour light/12-hour dark schedule at ambient temperature 
controlled between 22°C and 23°C under specific pathogen free conditions. Animals were given 
food and water ad libitum and maintained under veterinary supervision throughout the study. 
There was no evidence of disease among the colony. Mice of both sexes were randomly assigned 
to experimental groups (n=12 each for sham and injured animals). Two animals in the injury 
group were euthanized due to development of severe dermatitis of unknown reasons.  
Experiments were performed in accordance with Office of Laboratory Animal Welfare and 
National Institutes of Health guidelines under a protocol approved by the Roskamp Institute 
Institutional Animal Care and Use Committee (IACUC). All analyses were carried out blind to 
study group assignment.  
 
Experimental mTBI 
The experimental TBI methods were performed as previously described (29). Briefly, mice were 
anesthetized with 1.5 L per minute of oxygen and 3% isoflurane for 3 minutes. After shaving of 
the injury site, mice were transferred into a stereotaxic frame (Just For Mice Stereotaxic, 
Stoelting, Wood Dale, IL) mounted with an electromagnetic controlled impact device (Impact 
One Stereotaxic Motorized Impactor, Richmond, IL). Heads were positioned and fixed in the 
device, which prevented lateral movements as the impact was delivered. All mice were placed on 
a heating pad to maintain their body temperature at 37°C. A 5-mm blunt metal impactor tip 
attached to the electromagnetic motorized device was zeroed on the scalp and positioned above 
the midsagittal suture before each impact using the NeuroLab controller. On satisfactory 
positioning, the tip was retracted and the depth was adjusted to the desired level. The scalp was 
gently stretched by hand to restrict lateralization of the impact and to prevent the rod from 
delivering an inadequate trauma load at an irregular angle. Injury parameters were 5 m per second 
strike velocity, 1.0 mm strike depth, 200 milliseconds dwell time, and a force of 72N. This sub-
lethal impact does not cause direct tissue damage to the injury site, and there is no development 
of skull fracture or subdural hemorrhage, even after repetitive injuries. Mice in the r-mTBI group 
received 2 impacts every week for 3 or 4months (i.e. 24 or 32 impacts), with an inter-injury time 
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of 72-96hrs. Repetitive sham control mice received anesthesias of the same frequency and 
duration (~3mins per session) as their r-mTBI counterparts. Animals were grouped as repetitive 
shams or repetitive injury. This mixed paradigm was chosen to mimic the heterogeneity of 
cumulative mTBI exposures in the human setting. After each impact was delivered, the mice were 
allowed to recover on a heating pad set at 37°C to prevent hypothermia. On becoming 
ambulatory, mice were returned to their cages and carefully monitored for any abnormalities. 
 
Three chamber test for social interaction and novelty recognition test 
All neurobehavioral tests were conducted 6 months post first injury. Two social behaviors (social 
interaction and social memory/novelty recognition) were quantified using a rectangular three-
chamber test that includes a middle chamber with two doors leading to two separate (left and 
right) chambers, each containing a steel cage enclosure. After 5 minutes of habituation in the 
three chamber compartment, each mouse (experimental subject) was placed in the middle 
chamber and allowed to freely explore for 10 minutes, with the right chamber empty but an 
unfamiliar congener (Stranger I) held in the steel cage enclosure in the left chamber. Social 
interaction was determined by measuring the number of entries by the experimental subject into 
the chamber holding the unfamiliar congener vs the empty chamber. To measure social memory 
(or novelty recognition) a new novel stimulus mouse (stranger II) was subsequently placed in the 
previously empty right chamber.  The same parameters as above were measured to determine the 
preference of the experimental subject for stranger I or stranger II. 
 
Elevated plus maze 
The elevated plus maze consists of a plus shaped apparatus with two open and two enclosed arms, 
each with an open roof, elevated 50-70cm from the floor in a dimly lit room. Each mouse was 
placed at the junction of the four arms of the maze, facing the open arm. The mouse was allowed 
to freely maneuver within the maze for 5 mins; number of entries and duration in each arm 
(open/closed) were recorded with the aid of a video tracking system to evaluate anxiety effects 
based on a rodent’s aversion of open spaces.   
 
Open field test  
The open field was conducted in a large circular maze (120cm diameter) setup in a brightly lit 
room. Animals were placed in the center of the maze and the number of entries/time spent in a 
predefined center zone and around the walls of the maze was recorded over a 15 minutes trial to 
evaluate anxiety effects and sensorimotor activity. 
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Cerebral blood flow measurements 
Cerebral blood flow (CBF) was measured prior to euthanasia, six months post-first 
injurytimepoint. For CBF measurement, mice were anesthetized with a gas mixture of 3% 
isofluorane, 0.9 l min-1 nitrous oxide and 0.5 l min-1 oxygen. Animals were then immobilized on a 
mouse stereotaxic table and maintained under anesthesia with a mouse anesthetic mask (Kopf 
Instruments, Tunjunga, CA, USA) delivering 3% isofluorane, 0.5 l min-1 nitrous oxide, 0.3 l min-1 
oxygen. Rectal temperature was maintained at 37° C using a mice homeothermic blanket system 
(Harvard Apparatus, Holliston, MA, USA). An incision was made through the scalp and the skin 
retracted to expose the skull, which was then cleaned with a sterile cotton swab. Animals were 
maintained on a mixture of 1.5% isofluorane, 0.5 l min-1 nitrous oxide and 0.3 l min-1 oxygen. 
Cortical perfusion was measured with the Laser-Doppler Perfusion Imager from Moor 
Instruments (Wilmington, DE, USA) as previously described (42,43). A computer-controlled 
optical scanner directed a low-power He–Ne laser beam over the exposed cortex. The scanner 
head was positioned parallel to the cerebral cortex at a distance of 26 cm. The scanning procedure 
took 1 min and 21 seconds for measurements of 5538 pixels covering an area of 0.64cm2. At each 
measuring site, the beam illuminated the tissue to a depth of 0.5 mm. An image color-coded to 
denote specific relative perfusion levels was displayed on a video monitor. All images were 
acquired at 2-min intervals for a period of 30min (15 images for each animal). All images were 
stored in computer memory for subsequent analysis. For each animal, a square area of 0.05cm2 
(360 pixels) equally distributed between the right and left hemispheres was defined and applied to 
each image of the series in order to measure the CBF in the frontal and occipital cortex. CBF was 
also measured in the entire cortex by manually delineating for each mouse the cortex area (0.51-
0.54cm2 corresponding to 3504 to 3714 pixels). Relative perfusion values for each area studied 
were presented as percentage of CBF values in injured compared to sham controls. 
 
ELISA 
To obtain blood specimens to measure glucocorticoid and cytokine levels in plasma, animals 
were lightly anesthetized with isoflurane prior to euthanasia, and approximately 500μl of blood 
was withdrawn into EDTA capillary tubes by cardiac puncture. Samples were centrifuged at 
5000rcf for 3 minutes, and plasma samples (clear supernatant fraction) were flash frozen in liquid 
nitrogen and stored at  -80°C. Plasma glucocorticoid levels were measured using an ELISA kit 
purchased from Life-sciences-Invitrogen, Grand Island, NY. Cytokine levels (GM-CSF, IL-5, IL-
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6, IL-1β, TNFα, IL-17A, IL-10, IFNγ) were determined using Bio-Plex Pro mouse Th17 panel 8-
plex ELISA kit (Biorad, Hercules, CA), as instructed by the manufacturer’s guide. 
 
Brain Tissue preparation and Western Blotting 
Six months post first injury brain tissue was collected following transcardial perfusion by gravity 
drip with phosphate buffered saline (PBS). One hemisphere was extracted and dissected into two 
regions (cortex and corpus callosum), flash frozen in liquid nitrogen and kept at -80oC for 
antibody based/biochemical analyses. The other hemisphere was post-fixed in 4% 
paraformaldehyde (PFA) for histological/immunohistochemical (IHC) analyses.  
 
For western blotting analyses, the corpus callosum and cortex from each hemisphere were 
homogenized in 150µl and 750ul (respectively) of PBS (pH 7.4) containing proteinase inhibitor, 
using a probe sonicator. Homogenized samples were spun in a centrifuge at 15,000rpm for a few 
minutes and tissue supernatants were collected. Supernatant fractions were either denatured at 
95oC by boiling in Laemmli buffer (Bio-Rad, CA, USA) or prepared under non-denaturing 
conditions in Lammeli buffer without reducing agent. Samples were then subsequently resolved 
on 4–20% gradient polyacrylamide criterion gels (BioRad, CA, USA) or 4-12% gradient 
NuPAGE novex Bis-Tris precast polyacrylamide gels (Life Technologies, Grand Island, NY). 
After electrotransferring, polyvinylidene difluoride (PVDF) membranes were blocked in 5% milk 
made in tris buffered saline (TBS) and subsequently immunoprobed for different brain specific 
primary antibodies overnight (see Supplementary Table T1). After a rigorous washing step, 
membranes were probed with horseradish peroxidase (HRP) linked secondary antibodies (see 
Supplementary Table T1). For primary antibodies raised in mice, a 20% superblocking buffer was 
used in the secondary antibody solution. Immunoblots from cortical tissue samples were analyzed 
by using a housekeeping gene (Beta-actin or GAPDH antibody) to quantify the amount of 
proteins electrotransferred, and signal intensity ratios were quantified by chemiluminescence 
imaging with the ChemiDocTM XRS (Bio-Rad, CA, USA). Immunoblots from white matter 
tissue samples for non-reduced tau conformational antibodies were analyzed by using the most 
abundant bands from a total protein Coomassie stain as a control reference, and signal intensity 
ratios were quantified by chemiluminescence imaging with the ChemiDoc TM XRS.   
 
 
 
Immunohistochemistry  
 9 
Half brain hemispheres (left side) were embedded in 4% paraformaldehyde for <48hrs followed 
by paraffin embedding. Series of 6µm-thick sagittal sections were cut throughout the extent of the 
cortex and hippocampus guided by known bregma coordinates using a microtome (2030 Biocut, 
Reichert/ Leica, Buffalo Grove, IL). Cut sections were mounted onto positively charged glass 
slides (Fisher, Superfrost Plus, Pittsburgh, PA). 
 
Sections were deparaffinized in xylene and rehydrated in a decreasing gradient of ethanol before 
the immunohistochemical procedure. Sections were rinsed in distilled water and subsequently 
incubated at room temperature in a solution of endogenous peroxidase blocking solution, 
containing 3% hydrogen peroxide diluted in PBS for 15 minutes. For primary antibodies 
requiring antigen retrieval sections were either treated with (i) DAKO target retrieval citrate 
buffer solution (pH 6) for 8 minutes in the microwave, (ii) Tris-ethylene-diamine-tetraacetic acid 
–Tris - EDTA buffer (pH 8), or (ii) Proteinase K (IHC world, Woodstock, MD). Following 
antigen retrieval sections were blocked for 30mins to 1hr in either (i) Dako protein serum free 
protein block (Dako, Carpinteria, CA), (ii) normal blocking serum to which secondary antibody 
was raised or (iii) mouse immunoglobulin G blocking reagent mouse on mouse[MOM] Kit 
(Vectors Laboratories, Burlingame, CA). Sections were stained in batches with primary 
antibodies made up in supersensitive wash buffer or antibody diluent background-reducing agent. 
Primary antibodies used can be found in Supplementary Table T1. After overnight incubation, 
sections were rinsed with PBS and transferred to a solution containing the appropriate secondary 
antibody (Vectastain Elite ABC Kit, Vector Laboratories, Burlingame, CA) for 30mins to 1hr  
depending on the specific requirement of the antibody protocol. For antibodies raised in a mouse 
host, secondary antibodies were diluted in 20% superblock blocking buffer (Pierce, Thermo 
Fisher Scientific, Rockford, IL). After rinsing in water, sections were incubated with avidin-biotin 
horseradish peroxidase or alkaline phosphatase (AP) enzyme solution (Vectastain Elite ABC kit; 
Vector Laboratories, Burlingame, CA) solution for 30mins.  
 
Immunoreactivity was visualized with DAB (3,3 - diaminobenzidine) or Vector red AP substrate. 
Development with the chromogen was timed and applied as a constant across batches to limit 
technical variability before progressing to quantitative image analysis. The reaction was 
terminated by rinsing sections in copious amounts of distilled water. Mounted sections were 
progressed through a graded series of alcohols (dehydrated), cleared in xylene, and coverslipped 
with permanent mounting medium. The IHC procedure was previously validated for most 
antibodies used by including negative control sections, whereby the primary mouse monoclonal 
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antibodies were omitted and replaced, with either blocking agent or biotinylated secondary 
antibodies alone, to eliminate issues surrounding nonspecific immunoreactivity or detection of 
mouse immunoglobulin reacting with anti-mouse secondary in the tissue sample.  Immunoreacted 
sections were viewed using a motorized Olympus (BX63) upright microscope, and photographs 
were taken using the high resolution DP72 color digital camera. 
 
Histology  
Series of sections were deparaffinized and processed for different histological stains.  The Gallyas 
silver impregnation method was performed to reveal neurofibrillary tangles (NFTs) using a 
standardized protocol (see 40). Congo red staining for amyloid plaque was performed using 
manufacturers instructions (SIGMA, St. Louis, MO). Luxol fast blue (LFB) staining was 
performed to reveal myelination of axonal tracts within the white matter using a standardized 
staining procedure as previously described by Mouzon et al. (29). To detect microhemorrhages in 
the brain tissue a Prussian blue staining was also performed according to the manufacturer’s 
guidelines (ENG Scientific Inc, Clifton, NJ). Gallyas and Prusssian blue stained sections were 
counterstained with Nuclear fast red, while Luxol fast blue stained sections were counterstained 
with Cresyl violet. Counterstained sections were subsequently processed through a descending 
gradient of alcohol, xylene, and coverslipped with Permount mounting medium. 
 
Image Analysis and APP cell counts 
Immunoreactivity for cell markers (GFAP, IBA1) was measured by quantitative image analysis 
(optical segmentation). Rigorous staining protocols were applied to ensure consistency of 
immunostaining and accuracy of image analysis. Analysis was performed blind to experimental 
conditions using coded slides to avoid bias in evaluation. Multiple regions of interest were 
analyzed in standardized fashion for each cell marker/antibody.  First, a survey of immunostained 
tissue sections was performed independently to verify specific immunoreactivity that was 
subsequently progressed to quantitative image analysis. Briefly, non-overlapping red, green, blue 
(RGB) images were digitally captured randomly within the defined areas from each section 
(comprising an average of 5 sections per animal for each marker), providing a systematic survey 
of each region of interest for each animal within a group. A minimum of 15 microscopic fields 
(x60 magnification) was analyzed per region per animal. The total microscopic field yielding a 
total area of 3.5 mm2 analyzed for each region per animal. Immunoreacted profiles that were 
optically segmented were analyzed using CellSens morphometric image analysis software 
(Olympus, Center Valley, PA). A semiautomated RGB histogram-based protocol (specified in the 
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image analysis program) was used to determine the optimal segmentation (threshold setting) for 
immunoreactivity for each antibody. Immunoreactive profiles discriminated in this manner were 
used to determine the specific immunoreactive % area. Data were separately plotted as the mean 
percentage area of immunoreactivity per field (denoted ‘‘% area’’) ± SEM for each region and 
grouping. 
 
To assess changes in APP+ profiles in the corpus callosum, axonal profiles were determined from 
a series of 5 sections. Fifteen separate images spanning a total area of 3.52mm2 was examined. 
Only clearly distinguishable profiles with distinct morphological characteristics of axonal bulbs 
or swellings were included in the counts. Data were separately plotted as density estimates 
(number per mm2) ± SEM for the corpus callosum region and grouping. 
 
Volumetric estimates 
The volume of the corpus callosum of one brain hemisphere (bound by bregma co-ordinates -0.36 
to -0.72mm lateral) was determined by quantitative light microscopy using the Cavalieri method. 
In brief, sagittal sections containing the corpus callosum regions defined above were stained for 
Luxol fast blue (LFB) (taking every tenth serial section). An average of 5 sections were collected 
per animal. Mounted sections were viewed at low magnification and montage images of the entire 
corpus callosum region were electronically captured using a DP72 digital camera attached to a 
motorized Olympus BX63 digital photomicroscope (Olympus, Center Valley, PA).  Digital 
images were digitally outlined on each section using the Cell SENS Olympus software package. 
All analyses were carried out blind to study group assignment. For each animal, the volume of the 
corpus callosum region (bound by bregma co-ordinates -0.36 to -0.72mm lateral) was 
subsequently derived by multiplying the calculated total surface area by the mean distance 
between the series of sections. Data are presented as mean volume (in mm3) ± SEM per group. 
 
Lipidomic analyses 
Lipidomics analyses for different phospholipid species were conducted as follows: Lipids were 
extracted using the Folch method from the cortex as we have previously described (44) with 
addition of di-14:0 fatty acid containing internal standards for PE, PI, PG, PC PA, and 14:0 LPG, 
LPC and LPE, di-17:0 PS, PE, PC, PA, and PG, 14:LPE and LPC and 24:0 LPC. Lipidomic runs 
were performed in triplicate using SCID LC/MS as described elsewhere (44,45).  Identification 
and calculation of concentrations of specific lipid molecular species within each lipid class [LPC, 
LPE, PC, PI and SM levels] were calculated from the averaged MS spectrum across the 
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chromatographic peak for each lipid class using LipidomeDB software. Summed mass spectra for 
each lipid class in an LC/MS run were analyzed using LipidomeDB 
onlinehttp://lipidome.bcf.ku.edu:9000/Lipidomics/) to identify and quantify (with reference to 
added internal standards) each lipid molecular species. Each sample was analyzed in 
triplicate.The biological significance of changes in lipidomic profiles was evaluated using Lipid 
map pathway tools (www.lipidmap.org). Moreover, phospholipid classes were grouped according 
to the degree of unsaturation for the molecular species. For PC, ratios were calculated using 
docosahexaenoic acid (DHA)-containing species, PC (38:6, 16:0/22:6) and PC (40:7, 18:1/22:6), 
to arachidonic acid (AA)-containing species, PC (36:4, 16:0/20: 4), PC (38:4, 18:0/20:4), and PC 
(38:5, 18:1/20:4).  For PE, a ratio of DHA-containing species, PE (40:6, 18:0/22:6) and ether PE 
(ePE; 40:6, o-18:0/22:6), to AA-containing species, PE (38:4, 18:0/20:4) and ePE (38:4, o-
18:0/20:4), was calculated.  For PI, a ratio of DHA-containing PI (40:6, 18:0/22:6) to AA-
containing PI (36:4, 16:0/20:4) and PI (38:4, 18:0/ 20:4) species was examined. Group 
differences were determined using either ANOVA or the χ2 test based on the type of variable. 
When parametric assumptions were not met, values were log transformed for parametric analyses. 
Non-parametric testing was only used when transformation was found to be unsatisfactory. 
Principal Component Analysis (PCA) was used to minimize multicollinearity and achieve 
dimension reduction, as used routinely for the evaluation of lipidomic data (44, 45). The Kaiser-
Meyer-Olkin (KMO) and Bartlett’s test for sphericity were used to ensure sampling adequacy for 
PCA (KMO value of > 0.6 and Bartlett p < 0.05). Variables with eigenvalues of ≥1 were retained 
and PCA component were extracted using varimax with Kaiser normalization for rotation to 
simplify and clarify the data structure. In order to perform mixed linear modeling (MLM) 
regression analysis on each component (the outcome measure), the Anderson-Rubin method was 
used for exporting uncorrelated scores while adjusting for random (human) factor and assess 
independent fixed (diagnostic and replication). Following MLM, multiple-test corrections were 
performed with the Benjamin–Hochberg (B-H) procedure to control for the false discovery rate. 
Individual lipids were analyzed by MLM to identify lipids specifically altered by the study 
treatment. 
 
Statistical Analysis 
The relationships between mTBI and sham animals for western blotting, IHC, ELISA, 
neurobehavioral and CBF data were assessed by using either a parametric T-test or non-
parametric Mann Whitney U Test with a predefined criterion of p<0.05 to assess group 
differences. Data were assessed by the Kolmogorov-Smirnov test to evaluate if data sets fitted the 
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normal Gaussian distribution. All analyses were performed with SPSS 21.0 (IBM Corp., Armonk, 
NY) and Graph pad prism (La Jolla, CA) statistical software. 
 
Results 
 
Neurobehavioral observations  
We examined behavioral outcomes (six months post first injury) in our mouse model of chronic 
repeated TBI using the three-chamber test (social interaction and social novelty recognition or 
memory), open field (sensorimotor and anxiety) and elevated plus maze (anxiety).  No 
impairment in social interaction was observed in sham and injured animals, both groups of 
animals twice as frequently entered stranger I chamber compared to empty chamber 
(Supplementary Figure S1: A).  There was a trend (p=0.058) for diminished social memory in the 
injured group, with animals three times more frequently entering Stranger I chamber compared to 
new novel Stranger II chamber (Supplementary Figure S1: B). Sham animals behaved normally 
in the social novelty recognition test, frequenting Stranger II chamber >46% more than Stranger I 
chamber (Supplementary Figure S1: B). In both tests for anxiety, injured animals demonstrated 
more dis-inhibitory behavior than shams, with a trend towards increased exploration (i.e. time and 
frequency of entries) in the center zone of the open-field and open arms of the elevated plus maze 
tests (Supplementary Figure S6: E-F).  However, statistical analyses of these outcome measures 
did not reach significance.  Minimal changes were observed in the sensorimotor activity during 
the open field test; this was typified by a small trend towards decrease in motor activity in injured 
compared to sham animals (Supplementary Figure S6: D). 
 
Notably, five animals in the injured group presented with dermatitis around the skin of the face 
(around the eye region) and in some cases around the body, approximately 2-3 months into the 
study, following the first injury. This was probably due to lack of grooming and restrained use of 
front limbs following injury in these mice. Two of these animals that had severe dermatitis had to 
be euthanized, and the other three, which only had a milder form of dermatitis were also 
subsequently removed from the in vivo imaging and behavioral tests, which reduced our sample 
sizes. 
 
Cerebral blood flow  
Using a laser Doppler imaging system to assess changes in the cerebral blood flow of injured 
animals compared to their sham counterparts (Figure 1A) a reduction in CBF in the occipital 
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cortex was identified in injured compared to sham animals (p<0.01) (Figure 1B). No change was 
observed in the frontal cortex of either sham or injured animals; however, a trend towards 
decrease was observed in the entire cortex readings (Figure 1B).  
 
Neuropathology of chronic repetitive mTBI 
Macroscopic pathology 
The injury paradigm was consistent with a mild injury, with no evidence of macroscopic 
pathology in r-TBI exposed mice. Specifically there were no skull fractures or subdural 
hemorrhages and no gross pathological changes observed in any animals studied (Supplementary 
Figure S2: A,B).  
 
White matter pathology 
Prior examination of acute 24hr post-last injury brain tissue sections from this model depicted an 
exaggerated rise in APP+ axonal profiles in injured animals (212+ profiles per mm2) 
accompanied by an intense GFAP and IBA1 immunostaining in the corpus callosum (data not 
shown).  
 
At the chronic time point, a persistent increase in APP positive axonal profiles (Figure 2A-F) and 
extent of GFAP (Figure 3AB, DE, GH) and IBA1 (Figure 4DE, GH, JK) immunoreactivity was 
observed in the body and splenium of the corpus callosum in injured compared to sham animals. 
These changes were however, less prominent when compared to the 24hrs time point (data not 
shown).  
 
Axonal swellings immunopositive for APP (Figure 2 II', JJ', KK') were observed in the corpus 
callosum of injured animals, including hypertrophic astroglia (Figure 3 FF', II') and activated 
microglia (Figure 4 FF', II', LL'). These qualitative changes were confirmed by quantitative 
analyses of segmented profiles showing significant increases in APP+ profile density (5 fold), 
IBA1 (2 fold) and GFAP (1.85 fold) immunoreactivity levels in the corpus callosum of injured 
compared to sham animals (Figure 6A-C).  
 
S100ß immunoreactivity (an astroglial marker) was also notably increased in the cell body of 
astrocytes in the corpus callosum of injured compared to sham animals (Figure 3D, E see inset). 
Activated microglial cells were devoid of CD45 and MHCII immunostaining in injured animals 
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within the corpus callosum (data not shown). An increase in cellularity was observed in the 
corpus callosum of injured animals compared to shams (Figure 5E, F) using cresyl violet staining. 
 
An increase in GFAP immunoreactivity was also observed in the white matter regions of the 
walls of the lateral ventricles (Figure 3 CC', K). Notably, perivascular regions of the white matter 
of injured animals were prominently stained with GFAP (Figure 3J).  
 
No changes were observed in luxol fast blue [LFB] (Figure 5A-B) and myelin basic protein (data 
not shown) staining in the corpus callosum of injured compared to sham animals.  However, we 
did observe a significant thinning of the corpus callosum following stereological analyses of the 
volume difference between sham and injured animals. A 30% reduction was observed in the 
corpus callosum volume of injured compared to sham animals (see LFB; Figure 5C,D; Figure 
6D). 
 
Glial response (grey matter)  
There was a paucity in GFAP and IBA1 staining in the cortex of injured compared to sham 
animals (See Figure 3 A,B and Figure 4 A,B,CC' respectively).  This was confirmed by 
quantitative analyses (see Figure 6A,B). A notable increase in IBA1 and GFAP immunoreactivity 
was observed in the molecular cell layer (and white matter region) of the cerebellum of injured 
animals (Figure 3L). Intracellular APP immunostaining was increased in the cell body of 
pyramidal neurons in layers II-IV of the parietal cortex (Figure 2 G, H) 
 
Quantification of and immunolocalisation of tau 
Grey matter (cerebral cortex) 
In a substudy, analysis of brain tissue (grey matter) from mice subjected to this same injury 
paradigm but euthanized 24hrs after the last injury showed a 1.6 fold increase in total tau 
expression by immunoblotting in injured vs sham mice. However, immunohistochemistry did not 
show any changes for all other tau species analyzed (data not shown).  
 
For the chronic timepoint post-injury which is the focus of this manuscript, immunoblotting for 
total tau (DA9) again showed an increase in injured compared to sham animals in the grey matter 
(Figure 7A), however the chronic evaluation also revealed increases in pTau Thr231 (RZ3) and 
tau oligomers (TOC-1) (Figure 7B, E, F). This was confirmed by immunohistochemical analysis 
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for TOC-1 and RZ3 antibodies on serial sections of sham and injured animals; superficial layers 
of the cortex showed a mild increase in the immunoreactivity of TOC-1 and RZ3 (Figure 8A-D).  
 
Intriguingly no change was observed by immunoblotting for pTau 396/404 (PHF1) and S202 
(CP13) in sham and injured animals (Figure 7C,D). This was also confirmed by 
immunohistochemistry (see Supplemental Figure S3: A-F; I-K).  
 
Changes in conformational tau species positive for paired helical filaments and for the N terminal 
region of the phosphatase activating domain (PAD) was detected using the MC1 and TNT 
antibodies respectively. Immunoblotting showed no changes between sham and injured animals 
in the grey matter for either MC1 or TNT antibodies (Figure 7A, G, H). Likewise 
immunohistochemical analysis confirmed no augmentation in the immunoreactivity of MC1 and 
TNT in injured compared to sham animals (Supplemental Figure S4: A-C; D-G).  
 
Argyrophillic positive neurofibrillary and glial tangles were examined using the Gallyas silver 
stain. The cortices of both sham and injured animals were devoid of Gallyas staining 
(Supplemental FigureS3: G,H,L). Caspase cleaved truncated tau fragment (Tau C3 - Asp 421) 
showed no changes between sham and injured animals by immunohistochemistry (data not 
shown).  
 
 
White matter 
Changes in total tau (DA9), pTau (PHF1, CP13), PAD+ tau (TNT) and conformational tau 
species (TOC-1, MC1) were examined by immunoblotting or immunohistochemistry in the white 
matter of sham vs. injured animals, but no changes were observed (Figure 9A-F). Corresponding 
immunohistochemistry showed no changes in the white matter region of the corpus callosum.  
 
Neurofilament, synpatophysin, TDP-43, α-synuclein and amyloid 
Large caliber myelinated axonal damage in the grey matter was examined using neurofilament L 
protein marker (46); no changes were observed in sham compared to injured animals 
(Supplementary Figure S5: A,B). Synaptic integrity was determined using the presynaptic vesicle 
marker, synaptophsyin; we did not observe any injury-dependent changes in its expression 
(Supplementary Figure S5: A, C). 
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No changes were observed in total TDP-43 or α−synuclein levels in the grey matter of sham and 
injured animals (Supplementary Figure S5: A,D-E). There was no shift in molecular weight (kDa) 
of these proteins that could indicate an increase in their potentially pathogenic phosphorylated 
protein levels. Brain tissue from both sham and injured animals was devoid of Congo-red staining 
and 4G8 immunoreactivity (data not shown). 
 
Vascular response 
Levels of Claudin-5 and ZO1 were below limits of detection by western blotting using 
commercially available antibodies. No changes were observed in laminin or occludin levels in the 
grey matter between injured compared to sham animals (Supplementary Figure S5: F-G).  
Immunohistochemistry for laminin and collagen IV positive vessels showed no overt damage to 
the vasculature and an apparently similar vascular density between both shams and injured 
animals in different brain regions (Supplemental Figure S6:AA`-DD`).  
 
No evidence of extravasation of endogenous mouse IgG staining was observed in the cortical 
regions beneath the impact site in injured mice (Supplemental Figure S6: EE) and there was no 
evidence of microhemorrhages in the brain tissue of injured (or sham) animals examined by 
Prussian blue staining (Supplemental Figure S6: FF`).  
 
Brain phospholipid species profile 
No changes were observed in phosphatidycholine (PC) and phosphatidylinositol (PI) lipid species 
in injured versus sham animals (Supplementary Figure 7 A-B). However, an increase in total 
phosphatidylethanolamine (PE) and sphingomyelin (SM) lipid species were observed in injured 
compared to sham animals (Supplementary Figure 7 C-D). There was an increase in saturated 
fatty acid (SFA) classes of PE and SM lipid species in injured animals compared to shams (Figure 
8C-D). The mono-unsaturated fatty acid (MUFA) class of SM lipid species was also observed to 
significantly increase in injured compared to sham animals (Supplementary Figure 7D). Only PE 
lipid species showed an increase in their classes of polyunsaturated fatty acids (PUFA) in injured 
compared to sham animals (Figure 8C). We also measured arachidonic acid (AA) and 
docosahexaenoic acid (DHA) containing lipid species (Supplementary Figure 7E-G). A 
significant increase in AA containing lipid species for PC and PE was observed in injured 
compared to sham animals (Figure 8E, G). There was no change in DHA containing lipid species 
for PC and PI (Supplementary Figure 7E, F), but a significant increase in DHA containing PE 
species was observed in injured compared to sham animals (Supplementary Figure 7G). We 
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compared the AA:DHA ratio for PC, PE, PI lipid species. A significant increase in the AA:DHA 
ratio was observed for PE lipid species in injured vs sham animals (Supplementary Figure 7H), 
no changes were observed in PC and PI (data not shown).  
 
Neuroendocrine and inflammatory cytokine profiles in the plasma  
We found a significant decrease in IL-1β and IL-5 inflammatory cytokines in the plasma of 
injured compared to sham animals (Figure 10 A,B). No statistically significant changes were 
observed with the other inflammatory cytokines measured (GM-CSF, IFN-γ, TNF-, IL-10), 
however, a trend towards decrease in the injured group was noted in all cases (Figure 10 C-F). 
The changes in inflammatory cytokines correlated with an increase in the neuroendocrine marker, 
corticosterone, in the plasma of injured compared to sham animals (Figure 10 G).  
 
Discussion 
We have developed a new model with the intent to explore the chronic effects of repetitive, 
concussion-like mild TBI over a prolonged period of time in the hTau mouse model expressing 
all six human tau isoforms. In this first characterization we report persistent increases in total tau, 
tau oligomers and pTau (Thr231) species a few months after the cessation of injury and this may 
represent developing tau pathology in our model. Further studies examining extended chronic 
timepoints will be valuable to confirm progressive TBI dependent tauopathy in our model as this 
may have relevance to informing studies in CTE in humans exposed to a history of repetitive 
concussion/ mTBI.  In this first characterization we also report behavior (anxiety, cognition, 
sensorimotor) and neuropathology of exposure to chronic repetitive mTBI, and biochemistry of 
central and peripheral biomarkers.  
 
Neuropathological changes in grey and white matter after chronic r-mTBI 
The most conspicuous histopathological features seen in this animal model were found localized 
to the corpus callosum, consistent with observations with this same mTBI injury in our previous 
repetitive injury paradigm where 5 mTBI injuries were delivered with a 48h interval between 
each injury (29,33).  
These features included a pronounced and persistent ongoing axonal degeneration typified by 
increase APP positive profiles,  axonal swellings, bulbs and varicosities that were associated with 
corpus callosum thinning at chronic timepoints after the last-injury. Previous studies that have 
examined the effects of APP immunoreactivity in mouse models of repetitive mTBI typically 
show an initial rapid increase in APP staining (47, 48, 49), which we observed at the acute 24hrs 
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post-last injury timepoint in this study (a 30-fold increase vs controls). However, in other animal 
models, at subacute time points post-injury these effects diminish, with only non-existent or 
minor abnormalities seen between injury and aged-matched controls (47, 48; 49). In contrast, 
with our animal model we still observed a persistent ongoing increase in APP+ profiles following 
injury compared to shams, although these effects were significantly less prominent when 
compared to the acute effects observed 3-4 months earlier. Such inter-laboratory differences 
could be attributed to variations in experimental models and injury paradigms. For example our 
experimental device uses a flat tip impounder, whilst other groups mentioned typically use a 
rubber tip impounder that has been suggested to absolve the force of injury on the site of impact, 
making the injury more diffuse and less severe (40).We have also focused on chronicity of hits in 
this study at a level that has not been previously examined by most groups. Considering that mild 
head injury increases the vulnerability of the brain to a second concussive impact (47), it is 
plausible that in our current model, by design, there is a limited temporal window of recovery, 
resulting in the pronounced ongoing axonal degeneration evident months after injury. Other 
features observed in the corpus callosum include a robust astroglial and microglial activation. 
These degenerative white matter features observed in our model echo appearances documented in 
descriptions of human autopsy (12,13,50) and in vivo imaging (51) studies in TBI survivors, and 
at necropsy examination of brain tissue from a variety of repetitive mTBI animal models 
(28,31,33,36,39,46).  
 
In contrast to this ongoing white matter damage, there was no evidence of glial activation or 
ongoing axonal degeneration in grey matter, or of neuronal cell loss or structural damage to 
neuronal integrity in injured animals. However, immunoblots on material from grey matter did 
reveal a persistent increase (by two-fold) in total tau levels and this was accompanied by a 
significant increase in pTau Thr231 (RZ3+), tau oligomers (TOC-1+ [50, 52]), and a trend 
towards increase in tau conformer species (MC1+). In support of these observations, patchy 
immunoreactivity to these significantly altered tau species (RZ3, TOC-1) was shown in the 
superficial cortical layers of r-mTBI exposed animals. PHF1 (Ser394/404) and CP13 (Ser202) 
levels remained unchanged with injury. There was no evidence of the distinct perivascular 
accumulation of pTau immunoreactive neurons or glia, typical of human CTE; neither was there 
evidence of neuropil threads. At this stage we do not consider this model to represent a preclinical 
model of CTE, however, our findings appear to be among the first to show significant changes in 
tau oligomer levels at a chronic time point after repetitive mTBI in a mouse model. Small, 
misfolded tau species or tau oligomers are thought to be the toxic pathogenic species of tau which 
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are resistant to ubiquitination (see 53-57). They have been demonstrated both in vitro and in vivo 
to spread in a retrograde and anterograde manner from one neuron to another, within connected 
anatomical pathways (58). Whether these tau oligomeric species will inevitably form into beta-
pleated sheet conformation or fibrillary material is unknown. The specific changes in phospho-tau 
epitope pThr231 levels in our model, may also implicate the role of cis-trans conformational 
pTau changes after TBI in vivo. Cis-trans conformational pTau has been demonstrated to play an 
important role early in mild cognitive impairment, and they further accumulate in neurofibrillary 
degenerated neurons in Alzheimer’s disease and TBI (59, 60). We were not able to analyze these 
different conformational states in our studies, due to the lack of commercially available 
antibodies that can distinguish between cis from trans pThr231 pro-conformation in tau, therefore 
a definitive role of cis versus trans tau forms cannot be made in our study.  Further exploration in 
our model using these antibodies as well as others specific to different tau species at longer 
timepoints post-injury may be informative in this regard as this would confirm whether the 
persistent tau changes that we observe are on a continuum towards progressive TBI dependent 
neurofibrillary tau pathology. 
 
The TBI-dependent changes in tau reported herein are in contrast to our findings with our 
previous injury paradigm (five mTBI with a 48hr interval) in either C57BL/6 or hTau young mice 
(8-12 weeks old).  In those studies we did not observe any persistent changes in tau species 
following analyses of brain tissue by ELISA and immunohistochemistry, from 24hrs to 12 
months post-injury in either wild type or hTau mice (33, Mouzon et al., 2016 pers comm.).Other 
groups have also published data reporting absence of tau dependent changes following repeated 
injuries at acute to chronic timepoints (30,31,38).  Our findings suggest factors such as chronicity 
of impacts, age at exposure and frequency of injuries may play a role in precipitating tau 
pathologies at chronic timepoints after mTBI. This observation is supported by data from 
Petraglia and colleagues using a model of repeated mild traumatic brain injury in wild-type mice, 
said to recapitulate “subconcussive” injuries; the model involved 6 mTBIs per day (2hr intervals) 
for 7 days totaling 42 hits (36). Following this paradigm, the authors reported an increase in 
murine pTau levels by IHC at 7days, 1 month and 6 months post-injury. Intriguingly other 
models of chronic TBI exposure in younger mice involving fewer total injuries (ranging from 2-5 
mTBI) (28,32,34,37) and also in a single mouse model of blast related traumatic injury   (61,62) 
have reported significant changes in pTau levels immediately post-injury.  However, while these 
studies have reported acute alterations in tau, data on tau with chronic survival are not available 
from these models. 
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Thus far the majority of studies exploring effects of TBI on tau pathology have been conducted in 
young, wild-type mice which have a strong bias for the 4R murine tau isoform which some 
investigators have suggested to have a low propensity to form toxic tau aggregates in vivo. Our 
use of hTau transgenics may shed some light on the factors that influence propagation of (human) 
tau pathology after injury. hTau mice typically develop aggregated, hyper-phosphorylated tau by 
9 months of age, in a spatial temporally relevant distribution localized to regions such as the 
entorhinal cortex, subiculum and hippocampus, and by 15 months of age develop thioflavin-S-
positive neurofibrillary tangles, loss of neurons and apoptotic damage (41). In our previous work 
on aged hTau mice (>18months) exposed to 5 repetitive hits, we demonstrated augmentation of 
pTau pathology in superficial layers of the cortex and also in the hippocampus by 
immunohistochemistry (39). Of note, these effects appeared to be more pronounced than those 
observed in this current study using younger mice <13weeks at first injury, perhaps suggesting 
the importance of an underlying tau pathology at the time of injury as a vital trigger for 
precipitating persistent TBI-dependent tauopathy.  
 
In addition to tau we have also investigated other signature proteins related to neurodegeneration 
in our model. We found no evidence of amyloid pathology in repetitive mTBI injured animals, as 
determined by histopathology. To date, although the role of amyloid in CTE remains unknown, 
retrospective case studies have shown that a majority of CTE patients will have amyloid plaques 
at autopsy (13, 25). We also did not observe any changes in the levels of total neuronal 
transactive response DNA-binding protein - TDP43 (or its phosphorylated species) after injury. 
TDP43 has been identified as the major disease protein in frontal temporal lobar degeneration 
(FTLD) with ubiquitinated inclusions, and in amyotrophic lateral sclerosis (ALS). TDP43 
immunoreactive intraneuronal and intraglial inclusions are commonly described in CTE, and 
present in a majority of cases studied (13, 63-65). To our knowledge this among one of the first 
studies to asses TDP-43 levels at a chronic timepoint in a rodent repetitive mTBI model. 
Although our findings did not show any correlation between repetitive mTBI and TDP43, we are 
cautious when interpreting our findings regarding the role of TDP43 in r-mTBI, given that there 
might be differences between murine vs human TDP43. More studies need to be conducted to 
evaluate the role of this protein following TBI.  
 
Lipid dysfunction after chronic r-mTBI 
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Lipids are known to play an important role in neurological disorders and CNS injury, and have 
been implicated in TBI (66). We previously demonstrated TBI-dependent brain lipid changes in a 
controlled cortical injury (CCI) model using our lipidomic platform (67), and thus sought to 
evaluate changes in different lipid species in this new model. Our lipidomic analyses revealed an 
increase in total PE and SM lipid species in the cortex of our chronic repetitive mTBI exposed 
animals, accompanied by increases in saturated, mono or poly-unsaturated fatty acid classes of 
PE and SM lipid species. The reason for these lipid changes and their role in late TBI pathologies 
is not clear at this time, but we hypothesize may reflect: (i) dysregulation in brain lipid 
metabolism; (ii) failure of abluminal lipid transporters; or (iii) increased luminal transport from 
the periphery as free fatty acids or in esterified forms bound to lipoproteins. These high lipid 
levels after TBI could predispose to oxidative damage (i.e. lipid peroxidation), especially under 
inflammatory conditions. We additionally observed an increase in the ratio of arachidonic acid 
(AA - 20:4) to docosahexaenoic acid (DHA - 22:6) containing polyunsaturated lipid species in 
injured animals. Arachidonic Acid is metabolized to pro-inflammatory and vasoactive 
eicosanoids (such as, prostaglandins, leukotrienes and thromboxane) by lipoxygenase (LOX) 
and/or cycloxygenase (COX) pathways (66). Docosahexaenoic Acid, the most abundant 
polyunsaturated fatty acid, is metabolized by phospholipase A2 enzymes to produce metabolites 
resolvins and protectins, such as neuroprotectin D1 (68). These metabolites serve as an 
endogenous neuroprotectant that inhibits apoptosis, oxidative stress and pro-inflammatory 
processes (68-71). The consequences of this increase in AA to DHA ratio could, therefore, 
indicate an increase in pro-inflammatory versus anti-inflammatory environment at this late time 
point following exposure to chronic repetitive mTBI.  
 
Cerebral blood flow outcomes after chronic r-mTBI 
We observed a reduction in cerebral blood flow (CBF) in the head injured mice, localized 
primarily to the regions beneath the impact site around the occipital (/parietal) lobes.  
Intriguingly, in a study utilizing brain perfusion single photon emission computed tomography 
(SPECT) imaging in a cohort of >100 active and former American football players, the authors 
reported a decrease in brain perfusion, with a preponderance for the prefrontal lobe, temporal 
lobe, occipital lobe, and cingulate gyrus and hippocampus regions in their cohort (72). Although 
we cannot draw direct comparisons between our mouse CBF and human SPECT data, the 
similarities in the direction of change in brain perfusion highlights vascular dysfunction as 
another sequelae of TBI.  The reason behind this is unknown, given that we did not observe any 
focal injury or pathological changes in this region. Cerebral glucose metabolism has been linked 
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to reductions in blood flow after TBI and this could be possibly altered in our model (73). Of 
note, though we did not observe any impairment in blood brain barrier (BBB) integrity in control 
or injured animals, we did observe astroglial activation in perivascular regions in injured animals. 
Though observations in human, autopsy-derived material from patients surviving single moderate 
to severe TBI demonstrate widespread BBB disruption in a high proportion of both acute and late 
(>1 year survival) survivors (74), data on vascular pathology in CTE, in particular BBB integrity, 
are lacking.   
 
Neurobehavior, neuroendocrine and neuroimmune outcomes after chronic r-mTBI 
We conducted our behavioral analyses of hTau mice at 9 months of age. hTau mice typically do 
not show any significant impairment in spatial learning and memory until 12 months of age, 
although 6 month old mice have been noted by one group to show abnormal spatial learning 
compared to control mice (75, 76). Locomotor function, anxiety levels and gross motor functions 
are typically not different from age-matched controls (75). Our observations were conducted prior 
to the appearance of age-related neurobehavioral dysfunction to eliminate underlying 
confounding phenotypes. Behavioral evaluations report a pattern towards dis-inhibitory-like 
behavior and deficits in cognitive performance. The effects we report were more pronounced 
compared to our previously reported mTBI paradigms in young mice, which employed exactly 
the same level and nature of injury but investigated the effects of either a single or a different 
repetitive injury (5 hits over a 9day period) (29,33,39). Behavioral outcomes in our model could 
be attributed to underlying neuropathological correlates involving white-matter (corpus callosum) 
degeneration and accumulation of abnormal tau in neurons within the grey matter. Both sites of 
localized pathologies are relevant given their involvement in controlling dis-inhibitory behavior 
and cognitive function. Comparable behavioral outcome measures have also been reported in 
another repetitive mTBI model involving multiple “subconcussive” impacts; the authors observed 
cognitive deficits, increased risk taking, depression-like behavior, and sleep disturbances at 1 
month post exposure (36). However, this model differed from ours in that it was a much more 
concentrated paradigm with all the impacts occurring within a one week period.  Human patients 
exposed to a history of mTBI in contact sports demonstrate a spectrum of neurobehavioral 
symptoms including post-concussive syndrome (PCS) and chronic traumatic encephalopathy 
(CTE); involving alterations in mood, neuropsychiatric behavior, and cognition (77-84). 
 
Correlating with the neurobehavioral deficits seen in our model, we also observed an increase in 
the glucocorticoid steroid hormone, corticosterone.  Abnormalities in neuroendocrine function 
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and circadian rhythm have been shown after TBI of different severities (85-91). Upregulation in 
cortisol levels may result in an increased negative feedback to the brain via the HPA axis.  This 
can result in the dysregulation of sympathetic and autonomic nervous system functions implicated 
in the regulation of the fight or flight response (92). Neuroinflammatory cytokine levels in the 
periphery were also reduced in our model. Glucocorticoids, such as corticosterone, are known to 
influence a variety of immune-related functions (93), and can dampen down immune-
inflammatory cytokine signaling as seen in our model.  What specific effects down-regulation in 
systemic cytokine profiles may have on the injured brain is unknown and warrants further studies 
in the context of TBI. Our lipidomic studies did implicate a possible increase in baseline pro-
inflammatory response in the cortex based on the modest increase in arachidonic acid containing 
lipid species we found. A closer assessment of microglial cell markers (IBA1, CD45 and MHCII) 
showed a paucity of staining in the cortex in sham and injured animals. These findings are 
intriguing and may be a unique feature of this animal model. Very few studies exploring systemic 
inflammation and even brain neuroglial responses after repeated mTBI in humans have been 
conducted to date, it is therefore very difficult to draw a direct comparison between our model 
and what happens in the human setting. 
 
Conclusion  
In this study, we explored the effects of chronic repetitive mTBI in a mouse model with a human 
tau genetic background, with an injury paradigm designed to mimic the effects of repeated, mTBI 
injuries sustained over a prolonged timeframe. Our characterization encompasses the chronic 
histopathological, biochemical and neurobehavioral effects of these injuries after many months 
survival.  In this first characterization of our chronic TBI experiments, we confirm a two-fold 
increase in total tau levels and mild increases in tau oligomers/conformers and pre-tangle pTau 
(Thr231) species in the grey matter up to three months after cessation of injury, which we 
anticipate may be on a continuum of progressive TBI-dependent tauopathy.  Our data also 
confirm impairment in cerebral blood flow (hypo-perfusion), and a prominent feature of white 
matter damage typified by gliosis, axonal injury and corpus callosum thinning. These changes 
were also accompanied by increases in lipid species of different fatty acid classes and their 
secondary messengers. Subtle neurobehavioral deficits typified by dis-inhibition and deficits in 
cognitive performance were also observed. Together these data support the relevance of this 
concussive injury model in studying the consequences of repetitive mTBI in humans, and its 
usefulness in testing potential neuroprotective therapeutic strategies for chronic repeated mTBI.  
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Legends 
 
Figure 1: Cerebral blood flow in a hTau mouse model of chronic repeated TBI  
Two dimensional color coded cerebral microvascular blood flow maps recorded using the laser 
Doppler imager, shows flow data representing variation of regional blood cerebral blood flow in 
the cortex of sham and injured animals (A). Quantitative analysis of mean cerebral blood flow, 
obtained from 6 measurements per animal, demonstrates a significant reduction in the occipital 
cortex of injured compared to sham animals, a marginally significant decrease in the entire 
cortex, with no change observed in the frontal cortex (B). Data presented as percentage of sham. 
Blood flow velocity was visualized as a two dimensional color-coded map, and expressed in an 
arbitrary perfusion unit as cerebral blood flow flux. N= 6 (injured) or 8 (shams). Asterisks denote: 
** P<0.01.  
 
Figure 2: Axonal injury in a hTau mouse model of chronic repeated TBI 
Immunohistochemical staining for APP (axonal injury) demonstrated a significant increase in the 
corpus callosum (see white arrow in A, B) and this was localized within the body (C, D) and the 
splenium (E, F) of the corpus callosum. High power micrographs show APP accumulation along 
the length of damaged axons (II'), and in axonal bulbs or swellings (JJ', KK') throughout the 
entire length of the corpus callosum of injured animals.  Increased APP staining was observed in 
the cell body of pyramidal neurons in layer III of the parietal cortex of injured compared to sham 
animals (G,H). High power micrograph (LL') shows increase APP staining in the cell body and 
dendrites of injured axons.Abbreviation: CC (corpus callosum); HP (Hippocampus); SPL 
(Splenium).   
 
Figure 3: Astrogliosis in a hTau mouse model of chronic repeated TBI 
 
Immunohistochemical staining for GFAP (astrogliosis) demonstrated a dramatic increase along 
the length of the corpus callosum of injured animals compared to shams (A,B). Hypertrophic 
astrocytes were seen in the body (D, E) and splenium (G, H) of the corpus callosum of injured 
compared to sham animals. Hypetrophic astrocytes demonstrated large cell body and prominent 
thick processes in these regions (FF', II'). A parallel increase in astroglial marker S100ß,  was also 
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observed in the cell body of astroglial cells in the corpus callosum of injured compared to sham 
animals (see inset of D and E). White matter regions surrounding the ventricles also showed 
increased GFAP staining in the injured (C') compared to sham animals (C). High power 
micrograph of the ventricles can be seen in K. Prominent and hypertrophic perivascular astrocyte 
endfeet (strongly stained with GFAP) were observed along the length of small blood vessels in 
injured animals (J). Cerebellar injury was also present, and GFAP staining was significantly 
increased in the molecular cell layer in injured animals (L). Astroglial activation was not present 
in the cortex of injured animals (A, B).  Abbreviation: CC (corpus callosum); VTR (ventricles); 
CEREB (Cerebellum); Hippo (Hippocampus). 
 
Figure 4: Microgliosis in a hTau mouse model of chronic repeated TBI 
 
Immunohistochemical staining for IBA1 (microgliosis) demonstrated no change in the cortex of 
sham and injured animals (A, B). Microglial cells in the cortex had a quiescent morphology in 
both sham and injured animals (CC'). However, the corpus callosum showed strong 
immunostaining of IBA1 in injured animals (see body [C, D] and splenium [E,F and J,K] of the 
corpus callosum) compared to their sham counterparts. Higher power micrographs of activated 
microglial cells demonstrate a prominent cell body and short thick processes in injured animals 
(FF', II' and LL'). Abbreviation: CC (corpus callosum). 
 
Figure 5: Luxol fast blue (LFB) and cresyl violet immunostaining in a hTau mouse model of 
chronic repeated TBI 
 
Luxol fast blue (LFB) staining depict a prominent thinning of the corpus callosum region in 
injured compared to sham animals (A,B and C,D). LFB staining intensity appeared similar in 
both sham and injured animals. (G-J). Cresyl violet staining showed a dramatic increase in 
cellularity within this region in injured compared to sham animals (E, F) Abbreviation: SPL 
(splenium); CC (corpus callosum); Hippo (hippocampus).   
 
Figure 6: Quantitative assessment of GFAP, IBA1 and APP immunostaining and corpus 
callosum volume in a hTau mouse model of chronic repeated TBI 
 
GFAP and IBA1 immunostaining were significantly upregulated in the corpus callosum of 
injured compared to sham animals (A, B). No changes in GFAP and IBA1 was observed in other 
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regions (of grey matter) analyzed (A, B). APP+ spherical profiles in the corpus callosum was 
dramatically increased by ~6fold in the corpus callosum of injured compared to sham animals 
(C). The volume of the sub-region of the corpus callosum bound by bregma (-0.36 to -0.72mm 
lateral) was significantly reduced by ~30% in injured compared to sham animals (D). N=6 
(sham/injured) for A-C and N=4 (sham/injured) for D. Asterisks denote: *P<0.05; **P<0.01; 
***P<0.001. Abbreviation: CC (corpus callosum), P-Cortex (parietal cortex), DG (dentate gyrus). 
 
Figure 7: Quantitative assessment of total tau, pTau and conformational tau species in the 
grey matter by western blotting in a hTau mouse model of chronic repeated TBI  
 
Representative immunoblots for different tau antibodies is shown in A. Total tau (DA9), pTau 
Thr231 (RZ3), and tau oligomer (TOC-1) levels were significantly increased in injured compared 
to sham animals (B, E, F). The conformational tau antibody MC1 raised against neurofibrillary 
tangles was marginally increased in injured animals compared to sham animals. No changes were 
observed in pTau S396/404 (PHF1), pTau S202 (CP13), and tau+ N-terminal phosphatase 
activated domain (TNT) levels between sham and injured animals (C, D, H). Data are expressed 
as ratio of GAPDH or ß-actin levels. N=6-8 (sham/injured). Asterisks denote: *P<0.05; 
**P<0.01; ***P<0.001. 
 
Figure 8: Immunohistochemical assessment of conformational tau antibody TOC1 and 
phosphorylated tau antibody RZ3 (pThr231) in an hTau mouse model of chronic repeated 
TBI 
 
A notable increase in TOC-1 immunostaining was observed in the cortex of injured compared to 
sham animals (A-B). An increase in pTau Thr231 (RZ3) immunostaining in pyramidal neurons 
was also observed in layers II - IV of the cortex of injured compared to sham animals (C, D). 
High power micrographs inset B and D were taken from injured animals (see white box).   
 
Figure 9: Quantitative assessment of total tau, pTau, conformational tau species, alpha-
synuclein and neurofilament (NFL) in the white matter by western blotting in an hTau 
mouse model of chronic repeated TBI 
 
Representative immunoblots for different protein markers are shown in A. No changes were 
observed in total tau (DA9), pTau S202 (CP13), and tau+ N-terminal phosphatase activated 
 37 
domain (TNT) levels between sham and injured animals (B, C, D, F). A marginally significant 
increase was observed in tau oligomer (TOC-1) levels in injured compared to sham animals (E). 
No changes were observed in alpha-synuclein or neurofilament L (NFL) levels between sham and 
injured animals (G, H). Data are expressed as ratio of ß-actin or total protein levels. N=6-8 
(injured/sham).  
 
Figure 10: Inflammatory cytokine profile and corticosterone levels in the plasma of a hTau 
mouse model of chronic repeated TBI 
 
A significant decrease in IL-1ß and IL-5 was observed in the plasma of injured compared to sham 
animals (A,B). A trend towards decrease in GM-CSF, IFN-, TNF-, IL-10 was observed in injured 
compared to sham animals, however these did not reach statistical significance (C-F).  
N=10-12 (sham/injured). There was a significant increase in corticosterone in the plasma of 
injured animals compared to sham counterparts. N=6-8 (sham/injured). Asterisks denote: 
*P<0.05; **P<0.01. 
 
Supplementary Table T1: List of primary and secondary antibodies used in this study. 
 
Supplementary Figure S1: Neurobehavioral changes in a hTau mouse model of chronic 
repeated TBI 
 
The Three-chamber test demonstrated normal social interaction behavior in both sham and 
injured animals, with a notable trend for increased entries into the stranger I chamber compared to 
the empty chamber (A). In the social novelty recognition test for social memory, injured animals 
demonstrated a marginally significant decrease in entries into the new novel stranger II chamber 
compared to stranger I (B). The Open-field test showed that injured mice had a trend towards an 
increase in center-zone time compared to sham animals (C; see time-bins and total mean times 
inset), while sensorimotor activity pattern showed a trend towards reduction in injured compared 
to sham animals (D). None of these changes observed in the open field test were statistically 
significant. The Elevated plus maze test demonstrated an increase in time (E) and frequency of 
entries into the open arms (F), however this was also not statistically significant.  
 
Supplementary Figure S2: Macroscopic changes to the mouse brain following chronic 
repeated TBI  
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Mouse brains from sham and injured animals post perfusion are shown in A and B respectively. 
No gross pathological changes were observed in injured brains, both brains appeared normal, 
with no evidence of hemorrhages or skull fractures (see B inset).  
 
Supplementary Figure S3: Immunohistochemical assessment of phosho-tau antibodies and 
neurofibrillary tangles in a hTau mouse model of chronic repeated TBI 
 
Control hTau mice showed low expression of CP13 in the cortex (A), however, a strong 
immunostaining of CP13 was observed in the hippocampus, notably localized to the CA3 (C) and 
sibiculum (not shown) regions. No change in CP13 was observed between sham and injured 
animals in both the cortex and hippocampus areas (AB, CD). PHF1 immunoreactivity was low 
and undetectable in sham mice (E), and no change was observed between injured and sham 
control mice (E, F). Both sham and injured animals were devoid of Gallyas immunostaining for 
neurofibrillary tangles (G, H). For comparison, positive immunostaining for CP13 (I,J), PHF1 
(K), and Gallyas staining (L) are shown from aged P301L or aged hTau mice.  
 
Supplementary Figure S4: Immunohistochemical assessment of conformational tau 
antibodies in an hTau mouse model of chronic repeated TBI 
 
hTau mice showed low levels for MC1 and TNT antibodies by immunohistochemistry at 9 
months of age in sham mice (A, D). No changes were observed in both MC1 and TNT 
immmunostaining in the cortex between sham and injured animals (see A, B for MC1; and D, E 
for TNT).  For comparison, positive immunostaining for MC1 is shown from an aged P301L 
mouse (C); and also for TNT in dystrophic neurites from an aged PSAPP (F) and hTau mouse 
model (G).  
 
Supplementary Figure S5: Quantitative assessment of synaptic and axonal proteins, 
potentially pathogenic markers of neurodegeneration, and vascular associated proteins in 
the grey matter by western blotting in a hTau mouse model of chronic repeated TBI 
 
Representative immunoblots for different markers are shown in A. No changes were observed in 
levels of neurofilament L (NFL - axonal protein), synaptophysin (presynaptic marker), TDP43 or 
alpha-synuclein (markers of protein misfolding and neurodegeneration), laminin and occludin 
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(vascular and blood brain barrier integrity) in sham compared to injured animals. Data are 
expressed as ratio of GAPDH or ß-actin levels. N=6-8 (sham/injured).  
 
SupplementaryFigure S6: Immunohistochemical assessment of vascular markers in a hTau 
mouse model of chronic repeated TBI 
 
No change in collagen IV or laminin immunostaining pattern was observed in sham and injured 
animals in the grey or white matter (AA’-DD`). Images were captured from the midbrain (AA`), 
cerebellum (BB`), striatum (CC`) and pons-medulla (DD`). There was no evidence of 
extravasation of IgG molecules into the brain parenchyma in injured or sham animals (EE` from 
parietal cortex). Positive control from corpus callosum is shown inset in E` from a severe TBI 
mouse brain with subdural hemorrhage. Evidence of microhemorrhage was examined using 
Prussian blue staining for hemosiderin in combination with CD45 microglial cell marker in the 
brain parenchyma. There was no evidence of positive hemosiderin staining or hemosiderin-laden 
microglia/macrophages in the brain parenchyma (FF` from splenium). Positive staining for 
hemosiderin-laden macrophage is shown inset in F` from spleen for positive comparison. 
Abbreviations: COLL4 (Collagen IV); Pr-B (Prussian blue), HE (Haematoxylin); IgG 
(immunoglobulin).  
 
Supplementary Figure S7: Quantitative assessment of phospholipid species and AA:DHA 
lipid ratio in the cortex of a hTau mouse model of chronic repeated TBI 
 
Phosphatidylethanolamine (PE), Phosphatidylinositol (PI), sphingomyelin (SM) and 
phosphatidylcholine (PC/etherPC) were examined in cortical tissue homogenates of sham and 
injured animals. No changes were observed in total PC and PIin injured compared to sham 
animals (A, B). However, a significant increase in total PE and SM was observed in injured 
compared to sham animals (C-D). A significant increase in saturated and poly-unsaturated 
PEcontaining lipids was observed in injured animals compared to sham animals; no changes were 
observed in mono-unsaturated PE containing lipids (C). Both saturated and mono-unsaturated SM 
containing lipids were increased in injured compared to sham animals (D). No changes were 
observed in saturated, mono and poly-unsaturated PC and PI containing lipid species in injured 
compared to sham counterparts (A, B).  
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Arachidonic acid (AA) and docosahexaenoic acid (DHA) containing lipid species were calculated 
for PC, PI and PE. There was a significant increase in AA containing PC and PE species and a 
trend towards increase in PI species in injured compared to sham animals (E-G). No change was 
observed in DHA containing lipid species for PI (F), however, a significant increase was 
observed in DHA containing lipid species for PC and PE in injured compared to sham animals (E, 
G). The ratio of AA:DHA containing species for PE was significantly increased in injured 
compared to sham animals (H); a trend towards increase was also observed for AA:DHA 
containing species for PC and PI but this was not statistically significant (data not shown). N=5 
(sham/injured). Asterisks denote: *P<0.05; **P<0.01; ***P<0.001. Abbreviation: MUFA 
(monounsaturated lipid), PUFA (polyunsaturated lipid); AA (Arachidonic acid), DHA 
(docosahexaenoic acid). 
 
